Vishwas Seshadri net worth and biography

Vishwas Seshadri Biography and Net Worth

Dr. Vishwas (Vish) Seshadri, Ph.D., M.B.A., joined Abeona as Head of Research & Clinical Development in June 2021 and was appointed President and Chief Executive Officer, and member of the Company’s Board of Directors, in October 2021. Dr. Seshadri has more than 20 years of experience including academia and various senior and executive leadership roles in the life sciences industry overseeing product development, regulatory submissions, and commercialization for novel therapies including personalized, autologous cell and gene therapies. Prior to joining Abeona, Dr. Seshadri served in roles of increasing responsibility at Celgene Corporation, now a subsidiary of Bristol-Myers Squibb Company (BMS), where he focused on development and commercialization of novel therapies in hematology and oncology. Most recently, he led the team responsible for the launch of Breyanzi® (lisocabtagene maraleucel; liso-cel), an autologous CD19-directed chimeric antigen receptor (CAR) T cell therapy for relapsed or refractory large B-cell lymphoma. Previously, he was Head of Early-Stage Upstream Process Development for Biologics at Dr. Reddy's Laboratories. Dr. Seshadri completed his Ph.D. in Microbiology, Immunology & Molecular Biology and his post-doc in epigenetics at University of Arizona, and earned his M.B.A. in Finance and Healthcare from the Wharton School of the University of Pennsylvania.

What is Vishwas Seshadri's net worth?: The estimated net worth of Vishwas Seshadri is at least $5.79 million as of October 16th, 2025. Seshadri owns 1,189,818 shares of Abeona Therapeutics stock worth more than $5,794,414 as of December 5th. This net worth estimate does not reflect any other investments that Seshadri may own. Learn More about Vishwas Seshadri's net worth.
How do I contact Vishwas Seshadri?: The corporate mailing address for Seshadri and other Abeona Therapeutics executives is 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219. Abeona Therapeutics can also be reached via phone at 214-665-9495 and via email at [email protected]. Learn More on Vishwas Seshadri's contact information.
Has Vishwas Seshadri been buying or selling shares of Abeona Therapeutics?: During the past quarter, Vishwas Seshadri has sold $1,367.01 of Abeona Therapeutics stock. Most recently, Vishwas Seshadri sold 249 shares of the business's stock in a transaction on Thursday, October 16th. The shares were sold at an average price of $5.49, for a transaction totalling $1,367.01. Following the completion of the sale, the chief executive officer now directly owns 1,189,818 shares of the company's stock, valued at $6,532,100.82. Learn More on Vishwas Seshadri's trading history.
Who are Abeona Therapeutics' active insiders?: Abeona Therapeutics' insider roster includes Leila Alland (Director), Mark Alvino (Director), Michael Amoroso (CEO), Edward Carr (CAO), Faith Charles (Director), Brendan O'Malley (SVP), Vishwas Seshadri (CEO), Christine Silverstein (Director), Joseph Vazzano (CFO), and Todd Wider (Director). Learn More on Abeona Therapeutics' active insiders.
Are insiders buying or selling shares of Abeona Therapeutics?: During the last twelve months, insiders at the biopharmaceutical company sold shares 22 times. They sold a total of 351,238 shares worth more than $2,047,717.92. The most recent insider tranaction occured on November, 13th when Director Mark Alvino sold 15,000 shares worth more than $71,100.00. Insiders at Abeona Therapeutics own 6.9% of the company. Learn More about insider trades at Abeona Therapeutics.
Information on this page was last updated on 11/13/2025.

Vishwas Seshadri Insider Trading History at Abeona Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/16/2025	Sell	249	$5.49	$1,367.01	1,189,818
9/30/2025	Sell	25,000	$5.24	$131,000.00	1,190,067
9/29/2025	Sell	19,274	$5.39	$103,886.86	1,215,067
7/9/2025	Sell	69,420	$5.86	$406,801.20	1,234,341
6/6/2025	Sell	50,676	$6.76	$342,569.76	1,303,761
3/31/2025	Sell	25,000	$4.78	$119,500.00	1,355,322
4/25/2024	Buy	10,000	$3.20	$32,000.00	538,260
9/27/2023	Buy	20,000	$4.07	$81,400.00	521,731

Vishwas Seshadri Buying and Selling Activity at Abeona Therapeutics

Abeona Therapeutics Company Overview

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Today's Range

Now: $4.87

$4.69

$4.92

50 Day Range

MA: $4.99

$4.17

$5.66

2 Week Range

Now: $4.87

$3.93

$7.54

Volume

954,439 shs

Average Volume

2,466,979 shs

Market Capitalization

$263.91 million

P/E Ratio

3.96

Dividend Yield

N/A

Beta

1.12